Global X Japan Co. Ltd. Sells 26,299 Shares of Kenvue Inc. $KVUE

Key Points

• Global X Japan Co. Ltd. has reduced its stake in Kenvue Inc. by 50.1% during the second quarter, holding now 26,174 shares valued at approximately $548,000.
• Kenvue reported $0.29 earnings per share in its latest quarter, exceeding the consensus estimate of $0.28, although its revenue decreased by 4.0% year-over-year.
• The company recently declared a quarterly dividend increase to $0.2075 per share with a current annualized yield of 4.5%.

Global X Japan Co. Ltd. trimmed its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 50.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,174 shares of the company's stock after selling 26,299 shares during the period. Global X Japan Co. Ltd.'s holdings in Kenvue were worth $548,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Man Group plc acquired a new position in Kenvue during the fourth quarter worth $941,000. Waverly Advisors LLC increased its position in Kenvue by 79.5% during the fourth quarter. Waverly Advisors LLC now owns 18,536 shares of the company's stock worth $396,000 after buying an additional 8,209 shares during the last quarter. Vise Technologies Inc. acquired a new stake in shares of Kenvue in the fourth quarter valued at about $242,000. Neo Ivy Capital Management acquired a new stake in shares of Kenvue in the fourth quarter valued at about $8,229,000. Finally, Forum Financial Management LP grew its position in shares of Kenvue by 29.2% in the fourth quarter. Forum Financial Management LP now owns 22,917 shares of the company's stock valued at $489,000 after purchasing an additional 5,174 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

KVUE has been the topic of a number of recent research reports. Zacks Research raised Kenvue to a "strong sell" rating in a research report on Monday, August 11th. Royal Bank Of Canada decreased their target price on Kenvue from $24.00 to $22.00 and set a "sector perform" rating on the stock in a research report on Friday, August 8th. JPMorgan Chase & Co. decreased their target price on Kenvue from $27.00 to $26.00 and set an "overweight" rating on the stock in a research report on Friday, July 25th. Evercore ISI decreased their target price on Kenvue from $23.00 to $18.00 and set an "in-line" rating on the stock in a research report on Tuesday. Finally, UBS Group decreased their target price on Kenvue from $25.00 to $23.00 and set a "neutral" rating on the stock in a research report on Thursday, July 17th. Five analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $23.63.

Kenvue Price Performance

Shares of KVUE traded up $0.64 on Tuesday, hitting $17.61. The company's stock had a trading volume of 33,882,752 shares, compared to its average volume of 19,065,461. The company has a market capitalization of $33.79 billion, a PE ratio of 23.74, a PEG ratio of 2.63 and a beta of 0.83. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68. Kenvue Inc. has a fifty-two week low of $16.89 and a fifty-two week high of $25.17. The company has a 50 day moving average price of $20.77 and a 200 day moving average price of $22.00.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.28 by $0.01. The business had revenue of $3.84 billion for the quarter, compared to the consensus estimate of $3.94 billion. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.Kenvue's revenue was down 4.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were issued a $0.2075 dividend. This represents a $0.83 annualized dividend and a dividend yield of 4.7%. The ex-dividend date of this dividend was Wednesday, August 13th. This is an increase from Kenvue's previous quarterly dividend of $0.21. Kenvue's dividend payout ratio (DPR) is presently 112.16%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.